Jabbari, E; Zetterberg, H; Morris, HR; (2017) Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. Journal of Neurology, Neurosurgery & Psychiatry , 88 pp. 883-888. 10.1136/jnnp-2017-315857.

Preview	Text (Article) Jabbari_Tracking and Predicting Disease Progression in PSP - revisions final.pdf - Accepted Version Download (363kB) | Preview
Preview	Image (Figure 1) Diagram.jpg - Accepted Version Download (18kB) | Preview
Preview	Image (Figure 2) Flowchart.jpg - Accepted Version Download (21kB) | Preview
Preview	Text (Supplementary Table 1) Jabbari_Supplementary table.pdf - Accepted Version Download (201kB) | Preview

Abstract

Progressive supranuclear palsy (PSP) is a rare and progressive neurodegenerative condition characterised pathologically by neuronal cell loss due to abnormal tau deposits. Clinically, the condition manifests as parkinsonism with the addition of progressive balance, speech, swallowing, eye movement and cognitive impairment, ultimately leading to death. Measuring change over time in neurodegenerative conditions is central to defining the effects of therapeutic intervention and disease biology. The current gold standard for measuring clinical disease progression in PSP is the PSP Rating Scale score. However, such scales may be affected by intrarater and inter-rater variability. In addition, their use in clinical trials may be hindered by differences in the time interval between pathological disease progression/response to therapeutics and change in clinical state. Therefore, the need for reliable disease progression biomarkers to complement clinical rating scales is clear. Here we discuss the benefits of using biomarkers to predict and track disease progression in both clinical and research settings. Through reviewing the literature to date on the role of cerebrospinal fluid (CSF) and blood biomarkers, we highlight data that reveals the ability of CSF and plasma neurofilament light chain (NF-L) to predict and track clinical disease progression in PSP. We also discuss the need for large-scale longitudinal studies to identify novel biomarkers.

Download activity - last month

Export as CSVXMLJSON

Download activity - last 12 months

Export as XMLJSONCSV

Downloads by country - last 12 months

Export as CSVXMLJSON

Archive Staff Only

View Item